<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739048</url>
  </required_header>
  <id_info>
    <org_study_id>XH-16-011</org_study_id>
    <nct_id>NCT02739048</nct_id>
  </id_info>
  <brief_title>Changes of Immunologic Function in Patients of Prostate Cancer Induced After Cryoablation.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The overall objective of the study: By evaluating the curative effect of CSAP in localized&#xD;
      prostate cancer, locally advanced prostate cancer and metastasis advanced prostate cancer,&#xD;
      and the change of state in cellular immunity and humoral immunity before and after CSAP.&#xD;
      Validate the clinical therapeutic effect of all kinds of prostate cancer, as well as the&#xD;
      change of immune status before and after CSAP.&#xD;
&#xD;
      2. The main content of the study:&#xD;
&#xD;
        1. Included in the samples are patients in hospitals for CSAP. The sample capacity are&#xD;
           planned to be 80. The main purpose of the study is to observe the overall survival rate&#xD;
           , disease free survival rate, the progress time of the PSA biochemical recurrence as&#xD;
           well as the disease progress time.&#xD;
&#xD;
        2. Measure the change of concentration in peripheral blood T lymphocyte subsets (CD3 + T,&#xD;
           CD4 + T, CD8 + T, CD4 + / CD8 + T, NK cells) and regulatory T cells before and after&#xD;
           cryoablation within 1 month, 3 months and 6 months.&#xD;
&#xD;
        3. Measure the change of concentration in peripheral blood IFN-1, IL-4, IFN-1/IL-4 ratio&#xD;
           (Thl/Th2 ratio), and detect the secretion of CD4 + Th tumor-specific IFN-l and the&#xD;
           activity of tumor-specific killer CD8 + CTL before and after cryoablation within 2 weeks&#xD;
           and 1 month.&#xD;
&#xD;
        4. Before cryoablation, detect the expression and distribution of Follistatin-Like1&#xD;
           (FSTL-1), Besides, verify the connection between the number and activation ratio of&#xD;
           tumor local dendritic cells (DC) and the FSTL-1, evaluating the cryoablation effect on&#xD;
           the immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>humoral immunity and cellular immunity will be activated after CSAP for patients of prostate cancer</measure>
    <time_frame>3 years</time_frame>
    <description>All 80 participants' peripheral blood will be collected before CSAP and after CSAP to detect the concentration of T lymphocyte subsets (CD3 + T, CD4 + T, CD8 + T, CD4 + / CD8 + T, NK cells), IFN-1, IL-4, IFN-1/IL-4 ratio (Thl/Th2 ratio) and FSTL-1, and to comment the change of activity of humoral immunity and cellular immunity.</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        80 patients diagnose with prostate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients diagnosed with prostate cancer by pathology&#xD;
&#xD;
          -  the age of patients should be from 40 to 80 years old&#xD;
&#xD;
          -  do not receive other treatments like radical prostatectomy, radiotherapy, etc&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  can not receive surgery because of bad performance status&#xD;
&#xD;
          -  abnormal coagulation function&#xD;
&#xD;
          -  receive other treatment before CSAP&#xD;
&#xD;
          -  do not want to achieve CSAP because of any reasons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Kang, director</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Kang</last_name>
    <phone>+86-13901663058</phone>
    <email>kjjjjd@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Lin Wang, chief physician</last_name>
      <phone>+86-13901635510</phone>
      <email>wlhui@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jian Kang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

